Gunjur, Ashray http://orcid.org/0000-0001-9713-1872
Shao, Yan http://orcid.org/0000-0002-8662-0504
Rozday, Timothy
Klein, Oliver
Mu, Andre
Haak, Bastiaan W.
Markman, Ben http://orcid.org/0000-0002-0080-2842
Kee, Damien
Carlino, Matteo S.
Underhill, Craig http://orcid.org/0000-0001-9335-2678
Frentzas, Sophia
Michael, Michael
Gao, Bo
Palmer, Jodie
Cebon, Jonathan
Behren, Andreas http://orcid.org/0000-0001-5329-280X
Adams, David J. http://orcid.org/0000-0001-9490-0306
Lawley, Trevor D. http://orcid.org/0000-0002-4805-621X
Article History
Received: 23 June 2023
Accepted: 12 January 2024
First Online: 1 March 2024
Competing interests
: A.G. has received a speaker honorarium from Microbiotica Limited. B.M. has served on advisory boards for Amgen, Bristol Myers Squibb (BMS), Merck, Beigene and AstraZeneca (AZ). M.S.C. has served on advisory boards or as a consultant for Amgen, BMS, Eisai, Ideaya, Merck, Sharp & Dohme (MSD), Nektar, Novartis, Oncosec, Pierre-Fabre, Qbiotics, Regeneron, Roche, Merck, Moderna and Sanofi and received honoraria from BMS, MSD and Novartis. D.K. has served on advisory boards for BMS, MSD and Novartis. C.U. has served in a consulting/advisory role for Merck Serano and AZ and a speakers’ bureau role for IQvia and AZ. His institution has received research funding from Akeso Biopharma, Arcus Biosciences, Atridia, BeyondSpring Pharmaceuticals, Boehringer Ingelheim, Deciphera and Novotech. S.F. has received financial support from Amgen, MSD and AZ; honoraria for advisory boards from Akesobio, Ambrax and MSD; and institutional sponsorship/trials and research activities from Akesobio, Ambrax, Amgen, Axelia, AZ, Aulos, BeiGene, Cullinan, Daiichi Sankyo, Edison Oncology, Genentech, MSD, Takeda, HaiHe Biopharma, Vivace and WellMarker Bio. D.J.A. is a paid consultant for Ono Therapeutics and Microbiotica Limited and receives research support from AZ, OpenTargets and BMS. T.D.L. is cofounder and chief scientific officer at Microbiotica Limited. All other authors declare no competing interests.